@article{b86ed3ca127e403da43e083cf243811b,
title = "Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials",
abstract = "BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone. {\textcopyright} 2010 by the Infectious Diseases Society of America. All rights reserved.",
author = "Steigbigel, {Roy T.} and Cooper, {David A.} and Hedy Teppler and Eron, {Joseph J.} and Gatell, {Jose M.} and Kumar, {Princy N.} and Rockstroh, {Jurgen K.} and Mauro Schlechter and Christine Katlama and Martin Markowitz and Patrick Yeni and Loutfy, {Mona R.} and Adriano Lazzarin and Lennox, {Jeffrey L.} and Bonaventura Clotet and Jing Zhao and Hong Wan and Rhodes, {Rand R.} and Strohmaier, {Kim M.} and Barnard, {Richard J.} and Isaacs, {Robin D.} and Nguyen, {Bach Yen T.}",
year = "2010",
month = feb,
day = "15",
doi = "10.1086/650002",
language = "English",
volume = "50",
pages = "605--612",
number = "4",
}
